2022 World Conference on Lung Cancer (ePosters)-EP08.02-025. Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

EP08.02-025. Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

Back to course

Pdf Summary

Lazertinib, a third-generation tyrosine kinase inhibitor (TKI), has shown promising results as a frontline treatment for patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations. A Phase I/II trial was conducted to evaluate the safety and efficacy of Lazertinib in this patient population.<br /><br />The study included 43 patients who received Lazertinib at a dose of 240 mg. The treatment was well-tolerated, with a low incidence of EGFR-related toxicities such as rash and diarrhea. The risk for QTc prolongation, a measure of heart rhythm abnormalities, was also low, and no cardiotoxicity was observed.<br /><br />In terms of anti-tumor efficacy, Lazertinib demonstrated promising activity. The overall response rate was 70%, with 14% of patients achieving a complete response. The disease control rate was 86%, indicating that the majority of patients experienced tumor shrinkage or stable disease. The median progression-free survival was over 2 years, exceeding expectations for frontline therapy in this patient population.<br /><br />Based on these encouraging results, global phase 3 clinical trials are currently underway to further evaluate Lazertinib as a first-line treatment for EGFR-mutant NSCLC. One trial is evaluating Lazertinib as a monotherapy, while another is investigating its combination with amivantamab. These trials aim to confirm the efficacy and safety profile of Lazertinib in a larger patient population.<br /><br />Overall, Lazertinib 240 mg showed a favorable safety profile and promising anti-tumor activity as a frontline treatment for patients with EGFR-mutant advanced NSCLC. These findings support the ongoing clinical trials evaluating Lazertinib's potential as a standard of care in this patient population.

Asset Subtitle

Byoung Chul Cho

Meta Tag

Speaker Byoung Chul Cho

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Lazertinib

tyrosine kinase inhibitor

non-small cell lung cancer

EGFR mutations

Phase I/II trial

safety

efficacy

anti-tumor activity

progression-free survival

clinical trials